[FUNDING ANNOUNCEMENT] We are excited to share that ICE Bioscience has successfully closed its B++ round of financing. This achievement marks another substantial endorsement from the capital markets, following our significant fundraising effort in August 2023. 

As a high-growth CRO, this new funding will enable us to expand our cutting-edge services to the global pharmaceutical industry, enhancing our ability to support our clients in drug discovery and development. 

We are grateful for the trust and commitment from our financial partners as we continue to innovate and grow. Stay tuned for more updates as we further our mission to drive progress and support the pharmaceutical sector.

Published on May 16, 2024